Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zolacabtagene Autoleucel in cITP and AIHA
NCT07603557Phase 2Not yet recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2026
- Primary completion
- May 2030
- Modality
- CAR-T Cells
- Countries
- 4
01
Overview
A Phase 2 trial of BMS-986353 in immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), sponsored by Bristol Myers Squibb. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
BMS-986353
03
Conditions
immune thrombocytopenia (ITP)autoimmune hemolytic anemia (AIHA)
Beyond the preview
Go deeper on NCT07603557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07603557.